rhythm pharmaceuticals inc. is a biotechnology company located in 855 boylston street, 11th floor, boston, ma, united states.
Company profile
Ticker
RYTM
Exchange
Website
CEO
Hunter Smith
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
RHYTHM METABOLIC, INC.
SEC CIK
Corporate docs
Subsidiaries
Rhythm Pharmaceuticals Limited • Rhythm Securities Corp. • Rhythm Pharmaceuticals Netherlands, B.V. • Rhythm Pharmaceuticals UK Limited • Rhythm Pharmaceuticals France SAS • Rhythm Pharmaceuticals Italy S.r.L. • Rhythm Pharmaceuticals Canada Inc. • Rhythm Pharmaceuticals Germany GmbH • Xinvento, B.V. • Rhythm Pharmaceuticals Spain S.L. ...
RYTM stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
16 Apr 24
8-K
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
1 Apr 24
S-8
Registration of securities for employees
29 Feb 24
8-K
Entry into a Material Definitive Agreement
29 Feb 24
424B5
Prospectus supplement for primary offering
29 Feb 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
22 Feb 24
8-K
Regulation FD Disclosure
4 Jan 24
8-K
Entry into a Material Definitive Agreement
4 Jan 24
8-K
Amendments to Articles of Incorporation or Bylaws
18 Dec 23
Transcripts
RYTM
Earnings call transcript
2023 Q4
22 Feb 24
RYTM
Earnings call transcript
2023 Q3
7 Nov 23
RYTM
Earnings call transcript
2023 Q2
1 Aug 23
RYTM
Earnings call transcript
2023 Q1
2 May 23
RYTM
Earnings call transcript
2023 Q3
7 Mar 23
RYTM
Earnings call transcript
2022 Q4
1 Mar 23
RYTM
Earnings call transcript
2022 Q3
8 Nov 22
RYTM
Earnings call transcript
2022 Q2
2 Aug 22
RYTM
Earnings call transcript
2022 Q1
3 May 22
RYTM
Earnings call transcript
2021 Q4
1 Mar 22
Latest ownership filings
SC 13D/A
PERCEPTIVE ADVISORS LLC
17 Apr 24
4
Yann Mazabraud
16 Apr 24
4
Christopher Paul German
3 Apr 24
SC 13D/A
PERCEPTIVE ADVISORS LLC
3 Apr 24
4
Joseph Shulman
22 Mar 24
4
Jennifer Kayden Lee
22 Mar 24
144
Notice of proposed sale of securities
21 Mar 24
SC 13D
PERCEPTIVE ADVISORS LLC
20 Mar 24
144
Notice of proposed sale of securities
20 Mar 24
4
Hunter C Smith
19 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 64.92 mm | 64.92 mm | 64.92 mm | 64.92 mm | 64.92 mm | 64.92 mm |
Cash burn (monthly) | 17.03 mm | 10.04 mm | 14.65 mm | 15.43 mm | 9.75 mm | 11.73 mm |
Cash used (since last report) | 115.51 mm | 68.11 mm | 99.37 mm | 104.67 mm | 66.13 mm | 79.57 mm |
Cash remaining | -50.59 mm | -3.18 mm | -34.45 mm | -39.75 mm | -1.21 mm | -14.65 mm |
Runway (months of cash) | -3.0 | -0.3 | -2.4 | -2.6 | -0.1 | -1.2 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 147 |
Opened positions | 39 |
Closed positions | 13 |
Increased positions | 48 |
Reduced positions | 39 |
13F shares | Current |
---|---|
Total value | 1.55 tn |
Total shares | 74.75 mm |
Total puts | 50.20 k |
Total calls | 278.00 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
Primecap Management | 8.27 mm | $189.53 bn |
Baker Bros. Advisors | 6.70 mm | $153.65 bn |
BLK Blackrock | 6.20 mm | $142.13 bn |
Ra Capital Management | 5.68 mm | $130.12 bn |
GS Goldman Sachs | 5.16 mm | $118.31 bn |
Vanguard | 3.01 mm | $69.11 bn |
New Enterprise Associates 13 | 2.91 mm | $70.83 mm |
NEA Management | 2.91 mm | $66.71 bn |
Polar Capital | 2.50 mm | $57.31 bn |
Frazier Life Sciences Management | 2.37 mm | $54.36 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Apr 24 | Yann Mazabraud | RSU Common Stock | Grant | Acquire A | No | No | 0 | 10,000 | 0.00 | 10,000 |
15 Apr 24 | Yann Mazabraud | RSU Common Stock | Grant | Acquire A | No | No | 0 | 8,905 | 0.00 | 8,905 |
15 Apr 24 | Yann Mazabraud | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 6,874 | 0.00 | 0 |
15 Apr 24 | Yann Mazabraud | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 2,031 | 0.00 | 0 |
14 Apr 24 | Yann Mazabraud | Common Stock | Option exercise | Dispose M | No | No | 0 | 10,375 | 0.00 | 34,870 |
14 Apr 24 | Yann Mazabraud | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 10,375 | 0.00 | 31,125 |
2 Apr 24 | Christopher Paul German | Common Stock | Sell | Dispose S | No | Yes | 41.76 | 368 | 15.37 k | 795 |
21 Mar 24 | Joseph Shulman | Common Stock | Sell | Dispose S | No | Yes | 40.34 | 18,235 | 735.60 k | 30 |
20 Mar 24 | Jennifer Chien | Common Stock | Sell | Dispose S | No | Yes | 39.33 | 9,066 | 356.57 k | 6,852 |
20 Mar 24 | Jennifer Chien | Common Stock | Sell | Dispose S | No | Yes | 38.22 | 9,169 | 350.44 k | 15,918 |
News
Jim Cramer Is 'Willing To Let This Pharma Stock Catch Fire,' Advises Not To Sell McKesson
19 Apr 24
Wells Fargo Maintains Overweight on Rhythm Pharmaceuticals, Lowers Price Target to $52
18 Apr 24
5 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know
10 Apr 24
Needham Reiterates Buy on Rhythm Pharmaceuticals, Maintains $50 Price Target
10 Apr 24
Rhythm Pharmaceuticals Announces First Patient Dosed In Phase 1 Trial Evaluating RM-718
25 Mar 24
Press releases
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
18 Apr 24
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
16 Apr 24
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
11 Mar 24
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences
6 Mar 24
Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan
22 Feb 24